NASDAQ:NLSP NLS Pharmaceutics (NLSP) Stock Price, News & Analysis $3.83 +0.23 (+6.39%) (As of 12:50 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About NLS Pharmaceutics Stock (NASDAQ:NLSP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$3.69▼$4.7450-Day Range$0.12▼$5.3452-Week Range$3.51▼$29.08Volume10.50 million shsAverage Volume149,344 shsMarket Capitalization$14.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Read More… The centerpiece of Trump’s crypto’s masterplan … (Ad)Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”Click here to find out more about what could be Trump and JD Vance’s favorite coin. NLS Pharmaceutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks4th Percentile Overall ScoreNLSP MarketRank™: NLS Pharmaceutics scored higher than 4% of companies evaluated by MarketBeat, and ranked 962nd out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NLS Pharmaceutics.Read more about NLS Pharmaceutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioNLS Pharmaceutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.88% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently increased by 29.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNLS Pharmaceutics does not currently pay a dividend.Dividend GrowthNLS Pharmaceutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.88% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently increased by 29.18%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for NLS Pharmaceutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for NLSP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NLS Pharmaceutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about NLS Pharmaceutics' insider trading history. Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLSP Stock News HeadlinesCritical Survey: Takeda Pharmaceutical (NYSE:TAK) versus NLS Pharmaceutics (NASDAQ:NLSP)November 4 at 2:23 AM | americanbankingnews.comNLS Pharmaceutics Achieves Nasdaq Compliance MilestoneOctober 29, 2024 | markets.businessinsider.comRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. November 4, 2024 | Porter & Company (Ad)NLS Pharmaceutics regains full compliance with Nasdaq listing rulesOctober 29, 2024 | markets.businessinsider.comNLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing RequirementsOctober 28, 2024 | finance.yahoo.comNLS Pharmaceutics secures patent in Japan for Mazindol EROctober 22, 2024 | markets.businessinsider.comNLS Pharmaceutics Sees Reduced Losses Amid Financial ChallengesOctober 20, 2024 | finance.yahoo.comWhy Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?July 29, 2024 | investorplace.comSee More Headlines NLSP Stock Analysis - Frequently Asked Questions How have NLSP shares performed this year? NLS Pharmaceutics' stock was trading at $0.5899 on January 1st, 2024. Since then, NLSP stock has increased by 606.9% and is now trading at $4.17. View the best growth stocks for 2024 here. When did NLS Pharmaceutics IPO? NLS Pharmaceutics (NLSP) raised $20 million in an initial public offering on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NLS Pharmaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Palantir Technologies (PLTR) and Tesla (TSLA). Company Calendar Today11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NLSP CUSIPN/A CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.14 per share Price / Book0.32Miscellaneous Outstanding Shares3,815,000Free Float3,189,000Market Cap$13.73 million OptionableNot Optionable Beta-0.51 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:NLSP) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.